{"id":"sin-bev-tace","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Proteinuria"},{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Hepatic dysfunction"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Bevacizumab blocks vascular endothelial growth factor (VEGF) signaling to prevent new blood vessel formation that tumors depend on for growth. When combined with TACE—a minimally invasive procedure that delivers chemotherapy directly into the hepatic artery feeding the tumor while occluding blood flow—the dual mechanism targets both tumor vasculature and tumor cells directly, potentially improving efficacy in hepatocellular carcinoma.","oneSentence":"Sin-Bev-TACE is a combination therapy that pairs bevacizumab (anti-VEGF monoclonal antibody) with transarterial chemoembolization (TACE) to inhibit tumor angiogenesis while delivering chemotherapy directly to hepatic tumors.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:34:38.323Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatocellular carcinoma (HCC), intermediate to advanced stage"}]},"trialDetails":[{"nctId":"NCT05985798","phase":"PHASE3","title":"Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2023-08-01","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":258},{"nctId":"NCT04592029","phase":"PHASE1","title":"TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2020-09-27","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Sin-Bev-TACE","genericName":"Sin-Bev-TACE","companyName":"Second Affiliated Hospital of Guangzhou Medical University","companyId":"second-affiliated-hospital-of-guangzhou-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sin-Bev-TACE is a combination therapy that pairs bevacizumab (anti-VEGF monoclonal antibody) with transarterial chemoembolization (TACE) to inhibit tumor angiogenesis while delivering chemotherapy directly to hepatic tumors. Used for Hepatocellular carcinoma (HCC), intermediate to advanced stage.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}